32 Multiple Myeloma Clinical Trials in Houston, TX (2026)

Q: How do I join a clinical trial in Houston?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you.

Recruiting Multiple Myeloma Studies in Houston

NCT00477100Recruiting

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing sampl...

Houston, TX1,200 participantsM.D. Anderson Cancer Center

View Study Details

NCT05623020Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the ...

Houston, TXPHASE31,116 participantsPfizer

View Study Details

NCT06337097Recruiting

STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy

To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects....

Houston, TXNA980 participantsM.D. Anderson Cancer Center

View Study Details

NCT07222761Recruiting

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard tr...

Houston, TXPHASE3915 participantsRegeneron Pharmaceuticals

View Study Details

NCT05730036Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had adv...

Houston, TXPHASE3410 participantsRegeneron Pharmaceuticals

View Study Details

NCT05136807Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help do...

Houston, TX400 participantsM.D. Anderson Cancer Center

View Study Details

NCT07246590Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and s...

Houston, TXPHASE3300 participantsVerrica Pharmaceuticals Inc.

View Study Details

NCT07477587Recruiting

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple sub...

Houston, TXPHASE1258 participantsShanghai Henlius Biotech

View Study Details

NCT07210580Recruiting

Testing the Impact of Measurement-Based Care on Quality of Life and Disease Management Among Veterans With Inflammatory Bowel Disease

This research study is addressing issues related to Inflammatory bowel disease (IBD), which is a chronic autoimmune disorder that affects over 60,000 Veterans. With close monitoring and timely treatme...

Houston, TXNA250 participantsVA Office of Research and Development

View Study Details

NCT06698796Recruiting

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

The purpose of this study is to understand how the study medicine, dazukibart, works in people with active idiopathic inflammatory myopathies (dermatomyositis \[DM\] or polymyositis \[PM\]). Idiopath...

Houston, TXPHASE3211 participantsPfizer

View Study Details

NCT02726750Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no sig...

Houston, TX200 participantsM.D. Anderson Cancer Center

View Study Details

NCT05652335Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

The primary purpose of this study is to identify the recommended phase 2 dose (RP2D\[s\]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and to...

Houston, TXPHASE1180 participantsJanssen Research & Development, LLC

View Study Details

NCT07091630Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or pl...

Houston, TXPHASE3160 participantsargenx

View Study Details

NCT06639854Recruiting

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

The goal of this laboratory research study is to learn if interrupting a patient's letermovir dosing based on their immune system response can help HSC transplant patients avoid post-treatment CMV inf...

Houston, TXNA105 participantsM.D. Anderson Cancer Center

View Study Details

NCT02479698Recruiting

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that a...

Houston, TXPHASE2100 participantsM.D. Anderson Cancer Center

View Study Details

NCT05091372Recruiting

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

To increase the conversion rate from MRD-positive to MRD-negative CR in patients with newly diagnosed multiple myeloma (NDMM) receiving post-transplant maintenance therapy with belantamab mafodotin pl...

Houston, TXPHASE294 participantsM.D. Anderson Cancer Center

View Study Details

NCT04879043Recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma....

Houston, TXPHASE178 participantsHeidelberg Pharma AG

View Study Details

NCT06721013Recruiting

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and sa...

Houston, TXPHASE168 participantsEli Lilly and Company

View Study Details

NCT06988488Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRM...

Houston, TXPHASE162 participantsCelgene

View Study Details

NCT05776979Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT)....

Houston, TXPHASE261 participantsM.D. Anderson Cancer Center

View Study Details

NCT05053607Recruiting

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative...

Houston, TXNA50 participantsPack Health

View Study Details

NCT06434363Recruiting

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in comb...

Houston, TXPHASE147 participantsM.D. Anderson Cancer Center

View Study Details

NCT06066359Recruiting

Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help ...

Houston, TXPHASE144 participantsM.D. Anderson Cancer Center

View Study Details

NCT06536413Recruiting

ATRA and Carfilzomib in Plasma Cell Myeloma Patients

This is a Phase IB/II trial that will investigate the safety, tolerability and efficacy of combination therapy using All-Trans Retinoic Acid (ATRA) with Carfilzomib based therapies in plasma cell myel...

Houston, TXPHASE142 participantsThe Methodist Hospital Research Institute

View Study Details

NCT06207799Recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

To learn if giving elranatamab before and after an autologous stem cell transplant (ASTC) can help to control newly diagnosed, high-risk MM. An ASTC is a type of transplant in which a person's own ste...

Houston, TXPHASE240 participantsM.D. Anderson Cancer Center

View Study Details

NCT02291848Recruiting

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess n...

Houston, TXPHASE136 participantsBaylor College of Medicine

View Study Details

NCT06105554Recruiting

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 is to find the recommended dose of belumosudil mesylate that can be given to patients with relapsed/refractory MM. Phase 2 is to learn if the dose of belumosudil mesylate found in Phase 1 can...

Houston, TXPHASE136 participantsM.D. Anderson Cancer Center

View Study Details

NCT03953768Recruiting

VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems

Vagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for ...

Houston, TXNA30 participantsUniversity of Louisville

View Study Details

NCT04929236Recruiting

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

Houston, TXPHASE330 participantsOctapharma

View Study Details

NCT05336383Recruiting

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of sub...

Houston, TXPHASE230 participantsM.D. Anderson Cancer Center

View Study Details

NCT05055063Recruiting

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with hi...

Houston, TXPHASE130 participantsM.D. Anderson Cancer Center

View Study Details

NCT06730126Recruiting

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Background: Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called l...

Houston, TXPHASE215 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

About Multiple Myeloma Clinical Trials in Houston

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 32 multiple myeloma clinical trials recruiting participants in Houston, TX. These studies are seeking a combined 7,578 participants. Research is being sponsored by M.D. Anderson Cancer Center, Pfizer, Regeneron Pharmaceuticals and 14 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Houston — FAQ

Are there multiple myeloma clinical trials in Houston?

Yes, there are 32 multiple myeloma clinical trials currently recruiting in Houston, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Houston?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Houston research site will contact you about next steps.

Are clinical trials in Houston free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Houston studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 32 active trials in Houston are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 23, 2026 from ClinicalTrials.gov